Sign In
Buy PHAT
$8.23
-0.220 (-2.60%)
At Close: Aug 05, 2026
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of “Moderate Buy” by Analysts
01:12am, Thursday, 29'th Jan 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine ratings firms that are presently covering the stock, Marketbeat r
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
10:33pm, Wednesday, 07'th Jan 2026
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:05pm, Wednesday, 07'th Jan 2026
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
04:01pm, Wednesday, 07'th Jan 2026
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth
04:03pm, Friday, 21'st Nov 2025
Following Phathom's excellent financial results for Q3, its average price target rose to $23.13, which implies an upside of about 58.8% from its current stock price. Phathom Pharmaceuticals raised its
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Recommendation of “Moderate Buy” from Analysts
03:44am, Saturday, 15'th Nov 2025
Shares of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat report
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
08:00am, Tuesday, 04'th Nov 2025
First patient dosed, with topline results expected in 2027 pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (G
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
07:59am, Monday, 03'rd Nov 2025
FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript
01:26pm, Thursday, 30'th Oct 2025
Phathom Pharmaceuticals, Inc. ( PHAT ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Eric Sciorilli - Director of Business Development & Investor Relations Steven Basta - CEO
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
09:16am, Thursday, 30'th Oct 2025
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $1.32 per share a year ago.
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 30'th Oct 2025
Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expen
FLORHAM PARK, N.J., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
08:00am, Monday, 20'th Oct 2025
FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
